Download PDFPDF

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Re: Modulation of p38MAPK and STAT3 signalling by infliximab and etanercept in intestinal T-cells
    • Antonio Di Sabatino, MD
    • Other Contributors:
      • Rachele Ciccocioppo, Raffaele Morera, and Gino R. Corazza

    Dear Editor

    We thank Rosenstiel et al for their interest in our paper regarding the role of the chimeric anti-tumor necrosis factor (TNF)-alpha antibody, infliximab, in reverting defective lamina propria T-cell apoptosis in Crohn’s disease via a caspase-dependent pathway.[1]

    In their interesting letter Rosenstiel et al investigate the complex TNF-alpha blocker machinery in Crohn’s disease...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Modulation of p38MAPK and STAT3 signalling by infliximab and etanercept in intestinal T-cells
    • Philip Rosenstiel, MD
    • Other Contributors:
      • Jorgen Agnholt, Jens Kelsen, Valentina Medici, Georg H. Waetzig, Dirk Seegert and Stefan Schreiber

    Dear Editor

    There is growing evidence that the efficacy of anti-TNF-a therapies in Crohn’s disease (CD) may critically depend on the binding of the transmembrane precursor of TNF-a (mTNF-a), thus eliciting complex intracellular signaling events, a process described as ‘reverse signaling’.[1-3]

    In their recent paper, Di Sabatino et al.[4] have shown that infliximab reverts defective peripheral and la...

    Show More
    Conflict of Interest:
    None declared.